Zobrazeno 1 - 10
of 273
pro vyhledávání: '"Brodtkorb, M."'
Autor:
MacManus MP; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia; University of Melbourne, VIC, Australia. Electronic address: Michael.Macmanus@petermac.org., Seymour JF; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia; University of Melbourne, VIC, Australia., Tsang H; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia., Fisher R; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia., Keane C; Frazer Institute, University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia., Sabdia MB; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia., Law SC; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia., Gunawardana J; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia., Nath K; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Kazakoff SH; Queensland Institute of Medical Research Berghofer, Brisbane, QLD, Australia., Marques-Piubelli ML; MD Anderson Cancer Centre, Houston, TX, USA., Duenas DE; MD Anderson Cancer Centre, Houston, TX, USA., Green MR; MD Anderson Cancer Centre, Houston, TX, USA., Roos D; Royal Adelaide Hospital, Adelaide, SA, Australia., O'Brien P; Genesis Cancer Care, Newcastle, NSW, Australia., McCann A; Auckland City Hospital, Auckland, New Zealand., Tsang R; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Davis S; The Alfred, Melbourne, VIC, Australia., Christie D; Genesis Cancer Care, Tugun, QLD, Australia., Cheah C; Sir Charles Gairdner Hospital, Perth, WA, Australia., Amanuel B; PathWest Laboratory Medicine WA, Australia., Cochrane T; Gold Coast University Hospital, Gold Coast, QLD, Australia., Butler J; Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia., Johnston A; Royal Hobart Hospital, Hobart, TAS, Australia., Shanavas M; Mater Adult Hospital, Brisbane, QLD, Australia., Li L; Ochsner Health, New Orleans, LA, USA., Vajdic C; UNSW Kirby Institute, Sydney, NSW, Australia., Kridel R; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Shelton V; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Hershenfield S; Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Baetz T; Queen's University, Kingston, Ontario, Canada., Lebrun D; Queens Cancer Research Institute, Kingston, Ontario, Canada., Johnson N; McGill Centre for Translational Research in Cancer, Quebec, Canada., Brodtkorb M; Oslo University Hospital, Norway., Ludvigsen M; Aarhus University Hospital, Aarhus, Denmark., d'Amore F; Aarhus University Hospital, Aarhus, Denmark., Thompson ER; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia., Blombery P; Peter MacCallum Cancer Institute, Melbourne, VIC, Australia; University of Melbourne, VIC, Australia., Gandhi MK; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia. Electronic address: m.gandhi@uq.edu.au., Tobin JWD; Mater Research Institute, University of Queensland, Brisbane, QLD, Australia; Princess Alexandra Hospital, Brisbane, QLD, Australia. Electronic address: j.tobin@uq.edu.au.
Publikováno v:
EBioMedicine [EBioMedicine] 2024 Dec; Vol. 110, pp. 105468. Date of Electronic Publication: 2024 Dec 03.
Autor:
Hershenfeld SA; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Tobin JWD; Mater Research University of Queensland, Brisbane, Queensland, Australia.; Department of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia., Shelton V; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Calvente L; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Lajkosz K; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Liu T; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Brodtkorb M; Department of Oncology, Oslo University Hospital, Oslo, Norway., d'Amore FA; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Ludvigsen M; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark.; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark., Baetz T; Queen's University, Kingston, Ontario, Canada., LeBrun D; Department of Pathology and Molecular Medicine, Queen's University, Kingston, Ontario, Canada., Johnson N; Departments of Medicine and Oncology, Jewish General Hospital, Montreal, Quebec, Canada., Crump M; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Hong M; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Kuruvilla J; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Tremblay-LeMay R; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., MacManus M; Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Tsang R; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Hodgson DC; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada., Gandhi MK; Mater Research University of Queensland, Brisbane, Queensland, Australia.; Department of Haematology, Princess Alexandra Hospital, Brisbane, Queensland, Australia., Kridel R; Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada.
Publikováno v:
British journal of haematology [Br J Haematol] 2024 Nov; Vol. 205 (5), pp. 1810-1814. Date of Electronic Publication: 2024 Aug 07.
Autor:
Bai B; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Clinical Molecular Biology (EpiGen),, Akershus University Hospital, Lørenskog, Norway., Wise JF; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Vodák D; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Nakken S; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Centre for Bioinformatics, University of Oslo, Oslo, Norway., Sharma A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Brodtkorb M; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway., Hilden V; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Trøen G; Department of Pathology, Oslo University Hospital, Oslo, Norway., Ren W; Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Lorenz S; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Lawrence MS; Massachusetts General Hospital Cancer Center and Department of Pathology, Harvard Medical School, Charlestown, MA, USA.; Broad Institute of Harvard and MIT, Cambridge, MA, USA., Myklebost O; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Department for Clinical Science, University of Bergen, Bergen, Norway., Kimby E; Unit for Hematology and Department of Medicine at Karolinska Institutet, Huddinge, Stockholm, Sweden., Pan-Hammarström Q; Division of Immunology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden., Steen CB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Meza-Zepeda LA; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Beiske K; Department of Pathology, Oslo University Hospital, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway., Hovig E; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway.; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Centre for Bioinformatics, University of Oslo, Oslo, Norway., Lingjærde OC; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway.; Department of Informatics, University of Oslo, Oslo, Norway.; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Holte H; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. hhe@ous-hf.no.; Norwegian Cancer Genomics Consortium, CancerGenomics.no, Oslo, Norway. hhe@ous-hf.no.; Department of Oncology, Division for Cancer Medicine, Oslo University Hospital, Oslo, Norway. hhe@ous-hf.no., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway. j.h.myklebust@medisin.uio.no.; KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Oslo, Norway. j.h.myklebust@medisin.uio.no.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway. j.h.myklebust@medisin.uio.no.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2024 Aug 27; Vol. 14 (1), pp. 147. Date of Electronic Publication: 2024 Aug 27.
Autor:
Shelton V; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada., Detroja R; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada., Liu T; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada., Isaev K; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada., Silva A; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada.; Vector Institute, Toronto, ON, Canada., Passerini V; Department of Internal Medicine III, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany., Bakhtiari M; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada., Calvente L; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada., Hong M; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada., He MY; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada., Modi S; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada., Hershenfeld SA; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada., Ludvigsen M; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Madsen C; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Hamilton-Dutoit S; Department of Pathology, Aarhus University Hospital, Aarhus, Denmark., d'Amore FA; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.; Department of Hematology, Aarhus University Hospital, Aarhus, Denmark., Brodtkorb M; Department of Oncology, Oslo University Hospital, Oslo, Norway., Johnson NA; Jewish General Hospital, Montreal, QC, Canada., Baetz T; Department of Oncology, Queen's University, Kingston, ON, Canada., LeBrun D; Department of Pathology and Molecular Medicine, Queen's University, Kingston, ON, Canada., Tobin JWD; Mater Research University of Queensland, Brisbane, QLD, Australia.; Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia., Gandhi MK; Mater Research University of Queensland, Brisbane, QLD, Australia.; Department of Haematology, Princess Alexandra Hospital, Brisbane, QLD, Australia., Mungall AJ; Canada's Michael Smith Genome Sciences Centre at BC Cancer, Vancouver, BC, Canada., Xu W; Department of Biostatistics, Princess Margaret Cancer Centre, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada., Ben-Neriah S; BC Cancer, Vancouver, BC, Canada., Steidl C; BC Cancer, Vancouver, BC, Canada., Delabie J; Laboratory and Medicine Program, University Health Network, Toronto, ON, Canada., Tremblay-LeMay R; Laboratory and Medicine Program, University Health Network, Toronto, ON, Canada., Jegede O; Dana Farber Cancer Institute, Boston, MA, USA., Weigert O; Department of Internal Medicine III, Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany.; German Cancer Consortium (DKTK), Munich, Germany.; German Cancer Research Center (DKFZ), Heidelberg, Germany., Kahl B; Washington University, St. Louis, MO, USA., Evens AM; Rutgers Cancer Institute, New Brunswick, NJ, USA., Kridel R; Princess Margaret Cancer Centre-University Health Network, Toronto, ON, Canada. robert.kridel@uhn.ca.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2024 Aug 07; Vol. 14 (1), pp. 128. Date of Electronic Publication: 2024 Aug 07.
Autor:
Spasevska I; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Sharma A; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Steen CB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Division of Oncology, Stanford University School of Medicine, Stanford, CA., Josefsson SE; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Blaker YN; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Kolstad A; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Department of Oncology, Innlandet Hospital Trust, Lillehammer, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Rustad EH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Meyer S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Isaksen K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Chellappa S; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Kushekhar K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Beiske K; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Førsund MS; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Spetalen S; Division of Cancer Medicine, Department of Pathology, Oslo University Hospital, Oslo, Norway., Holte H; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Østenstad B; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Brodtkorb M; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Division of Cancer Medicine, Department of Oncology, Oslo University Hospital, Oslo, Norway., Kimby E; Department of Hematology, Karolinska Institute, Stockholm, Sweden., Olweus J; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.; Institute of Clinical Medicine, University of Oslo, Norway., Taskén K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway., Newman AM; Division of Oncology, Stanford University School of Medicine, Stanford, CA.; Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA., Lorenz S; Department of Core Facilities, Geonomics Core Facility, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Alizadeh AA; Division of Oncology, Stanford University School of Medicine, Stanford, CA.; Divisions of Hematology & Oncology, Department of Medicine, Stanford University, Stanford, CA., Huse K; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway., Myklebust JH; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B-cell malignancies, Institute of Clinical Medicine, University of Oslo, Norway.; Precision Immunotherapy Alliance, University of Oslo, Oslo, Norway.
Publikováno v:
Blood advances [Blood Adv] 2023 Dec 12; Vol. 7 (23), pp. 7216-7230.
Autor:
Leich E; Institute of Pathology, University of Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany., Brodtkorb M; Department of Oncology, Oslo University Hospital, Oslo, Norway., Schmidt T; Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany., Altenbuchinger M; Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.; Department of Medical Bioinformatics, University Medical Center Göttingen, Göttingen, Germany., Lingjærde OC; Division of Biomedical Informatics, Department of Computer Science, University of Oslo, Norway., Lockmer S; Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden., Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway., Nedeva T; Institute of Pathology, University of Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany., Grieb T; Institute of Pathology, University of Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany., Sander B; Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm, Sweden., Sundström C; Department of Pathology, Uppsala University Hospital, Uppsala University, Uppsala, Sweden., Spang R; Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany., Kimby E; Division of Hematology, Department of Medicine at Huddinge, Karolinska Institutet, Stockholm, Sweden., Rosenwald A; Institute of Pathology, University of Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, Germany.
Publikováno v:
Leukemia & lymphoma [Leuk Lymphoma] 2023 Dec; Vol. 64 (12), pp. 1927-1937. Date of Electronic Publication: 2023 Sep 08.
Autor:
Isaksen KT; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B cell malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo., Galleberg R; Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen., Mastroianni MA; Department of Hematology, Akershus University Hospital, Lorenskog., Rinde M; Department of Hematology, Vestfold Hospital Trust, Tonsberg., Rusten LS; Department of Surgery, Section of Oncology, Drammen Hospital, Vestre Viken Hospital Trust, Drammen., Barzenje D; Department of Oncology, Ostfold Hospital Trust, Kalnes., Ramslien F; Department of Hematology, Telemark Hospital Trust, Skien., Fluge O; Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway; Department of Clinical Science, University of Bergen., Slaaen M; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; The Research Centre for Age Related Functional Decline and Diseases, Innlandet Hospital Trust, Ottestad., Meyer P; Stavanger University Hospital-Rogaland, Stavanger., Liestol K; Department of Informatics, University of Oslo, Oslo, Norway; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; KG Jebsen Centre for B cell malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo., Lingjarde OC; Department of Informatics, University of Oslo, Oslo, Norway; Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo., Holte H; KG Jebsen Centre for B cell malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo., Brodtkorb M; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Oncology, Oslo University Hospital, Oslo. meide@ous-hf.no.
Publikováno v:
Haematologica [Haematologica] 2023 Sep 01; Vol. 108 (9), pp. 2454-2466. Date of Electronic Publication: 2023 Sep 01.
Autor:
Østenstad, B., Pirosa, M. C., Schär, S., Brodtkorb, M., Wahlin, B. E., Hernberg, M., Pedersen, M., Stathis, A., Zander, T., Novak, U., Zenz, T., Fischer, N., Krasniqi, F., Hitz, F., Jjohansson, A., Lofgren, D., Meyer, P., Bjørnevik, A. T., Hayoz, S., Scheibe, B.
Publikováno v:
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p117-119, 3p
Autor:
Isaksen KT; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Mastroianni MA; Department of Hematology, Akershus University Hospital, Lørenskog, Norway., Rinde M; Department of Hematology, Vestfold Hospital Trust, Tønsberg, Norway., Rusten LS; Section of Oncology, Department of Surgery, Drammen Hospital, Vestre Viken Hospital Trust, Drammen, Norway., Barzenje DA; Department of Oncology, Østfold Hospital Trust, Kalnes, Norway., Ramslien LF; Department of Hematology, Telemark Hospital Trust, Skien, Norway., Slaaen M; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; The Cancer Unit, Hamar Hospital, Innlandet Hospital Trust, Hamar, Norway., Jerm MB; Cancer Registry of Norway, Department of Registration, Oslo, Norway., Smeland EB; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway., Rostoft S; Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Geriatric Medicine, Oslo University Hospital, Oslo, Norway., Liestøl K; Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway.; Department of Informatics, University of Oslo, Oslo, Norway; and., Brodtkorb M; Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.; KG Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway., Holte H; KG Jebsen Centre for B Cell Malignancies, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department of Oncology, Oslo University Hospital, Oslo, Norway.
Publikováno v:
Blood advances [Blood Adv] 2021 Nov 23; Vol. 5 (22), pp. 4771-4782.
Autor:
Nogueira, Daniel Silva1,2 (AUTHOR) nogueira.hemato@gmail.com, Lage, Luís Alberto de Pádua Covas1,2 (AUTHOR) cadiele.reichert@hc.fm.usp.br, Reichert, Cadiele Oliana1,2 (AUTHOR) hebert.culler@hc.fm.usp.br, Culler, Hebert Fabrício1,2 (AUTHOR) fabio.alessandro@hc.fm.usp.br, de Freitas, Fábio Alessandro1,2 (AUTHOR) spbydlow@usp.br, Mendes, João Antônio Tavares2 (AUTHOR), Gouveia, Ana Carolina Maia2 (AUTHOR), Costa, Renata de Oliveira3 (AUTHOR) renatadeoliveiracosta@uol.com.br, Ferreira, Cristiane Rúbia4 (AUTHOR) rubia082@gmail.com, Maximino, Jéssica Ruivo5 (AUTHOR) jessica.maximino@fm.usp.br, Bydlowski, Sérgio Paulo1,6 (AUTHOR) d.levy@hc.fm.usp.br, Murga Zamalloa, Carlos Alejandro7 (AUTHOR) catto@uic.edu, Rocha, Vanderson1,2,8,9 (AUTHOR) juliana.pereira@hc.fm.usp.br, Levy, Débora6 (AUTHOR), Pereira, Juliana1,2,10 (AUTHOR)
Publikováno v:
Cancers. Dec2024, Vol. 16 Issue 23, p3914. 24p.